Update in Precision Oncology in Non-small Cell Lung Cancer

Author:

Riano Ivy1,Abuali Inas2,Abrams Hannah3,Khan Moiz4,Adjei Alex A5,Neal Joel6,Das Millie7

Affiliation:

1. Dartmouth Cancer Center, Hanover, NH, USA

2. Mass General Cancer Center, Boston, MA, USA

3. Fred Hutchinson Cancer Center, Seattle, WA, USA

4. Karmanos Cancer Institute, Detroit, MI, USA

5. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA

6. Stanford Cancer Institute, Palo Alto, CA, USA

7. Palo Alto VA Health Care System, Palo Alto, CA, USA

Abstract

Treatments for lung cancer have historically been considered “one-size-fits-all” The development of Precision Oncology, however, has led to increased recognition of non-small cell lung cancer (NSCLC) as a molecularly complex amalgam of diseases with differing outcomes. The 2023 Precision Oncology Summit was held in San Francisco on October 7th and 8th, focused on actionable strategies addressing personalized treatment to improve outcomes of patient with lung cancer. This manuscript summarizes the discussion and key learning points from the precision medicine clinical science symposium in NSCLC, including the latest translational science, and clinical applications updates.

Publisher

Binaytara Foundation

Reference17 articles.

1. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002);A. Inoue;Annals of Oncology,2013

2. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC;Suresh S. Ramalingam;New England Journal of Medicine,2020

3. FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations;News release. FDA,2018

4. Osimertinib in resected EGFR-mutated non–small-cell lung cancer;Jie He;New England Journal of Medicine,2020

5. FDA approves first adjuvant therapy for most common type of lung cancer;News release. FDA,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3